These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Neuroimaging in mild cognitive impairment]. Fukuyama H Rinsho Shinkeigaku; 2006 Nov; 46(11):791-4. PubMed ID: 17432181 [TBL] [Abstract][Full Text] [Related]
24. [Pharmacotherapy of Alzheimer's disease--an evidence based approach]. Boban M; Mahović-Lakusić D; Babić T Lijec Vjesn; 2004; 126(7-8):211-4. PubMed ID: 15754792 [TBL] [Abstract][Full Text] [Related]
25. [J-ADNI and very early treatment of Alzheimer's disease]. Iwatsubo T Nihon Ronen Igakkai Zasshi; 2012; 49(3):300-2. PubMed ID: 23268968 [No Abstract] [Full Text] [Related]
27. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Ito K; Corrigan B; Zhao Q; French J; Miller R; Soares H; Katz E; Nicholas T; Billing B; Anziano R; Fullerton T; Alzheimers Dement; 2011 Mar; 7(2):151-60. PubMed ID: 20810324 [TBL] [Abstract][Full Text] [Related]
28. Clinical and research diagnostic criteria for Alzheimer's disease. Sarazin M; de Souza LC; Lehéricy S; Dubois B Neuroimaging Clin N Am; 2012 Feb; 22(1):23-32,viii. PubMed ID: 22284731 [TBL] [Abstract][Full Text] [Related]
29. Harnessing diversity to study Alzheimer's disease: A new iPSC resource from the NIH CARD and ADNI. Screven LA; Pantazis CB; Andersh KM; Hong S; Vitale D; Lara E; Ku RY; Heutink P; Meyer J; Faber K; Nho K; Saykin AJ; Foroud TM; Nalls MA; Blauwendraat C; Singleton A; Narayan PS Neuron; 2024 Mar; 112(5):694-697. PubMed ID: 38387456 [TBL] [Abstract][Full Text] [Related]
30. Alzheimer's biomarker initiative hits its stride. Miller G Science; 2009 Oct; 326(5951):386-9. PubMed ID: 19833956 [No Abstract] [Full Text] [Related]
31. [Beta- and gamma-secretases]. Iwatsubo T Rinsho Shinkeigaku; 2006 Nov; 46(11):925-6. PubMed ID: 17432221 [TBL] [Abstract][Full Text] [Related]
33. Utility of imaging for nutritional intervention studies in Alzheimer's disease. de Wilde MC; Kamphuis PJ; Sijben JW; Scheltens P Eur J Pharmacol; 2011 Sep; 668 Suppl 1():S59-69. PubMed ID: 21816137 [TBL] [Abstract][Full Text] [Related]
34. Introduction. Alzheimer's disease: from research to practice. Schneider LS J Clin Psychiatry; 1998; 59 Suppl 11():3. PubMed ID: 9731542 [No Abstract] [Full Text] [Related]
35. Commentary on "Biomarkers in Alzheimer's disease drug development." The view from Alzheimer's Disease Neuroimaging Initiative. Weiner MW Alzheimers Dement; 2011 May; 7(3):e45-7. PubMed ID: 21575867 [No Abstract] [Full Text] [Related]
36. [New conception of Alzheimer's disease and the strategy for preclinical therapy]. Miyagawa T; Iwata A Nihon Rinsho; 2011 Dec; 69 Suppl 10 Pt 2():252-6. PubMed ID: 22755193 [No Abstract] [Full Text] [Related]
37. A call to arms for clinical research in Alzheimer's disease. Lehmann HE Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):xvii-xix. PubMed ID: 3797681 [No Abstract] [Full Text] [Related]
38. Research and development challenges for Alzheimer's disease drug discovery. Krafft GA Neurobiol Aging; 1994; 15 Suppl 2():S57-9. PubMed ID: 7700463 [No Abstract] [Full Text] [Related]
39. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: preface: pharmacological/underlying interventions for Alzheimer's disease. Nomura Y J Pharmacol Sci; 2012; 118(3):317-8. PubMed ID: 22382660 [No Abstract] [Full Text] [Related]
40. Idalopirdine for Alzheimer's disease: written in the stars. Schneider LS Lancet Neurol; 2014 Nov; 13(11):1063-1065. PubMed ID: 25297011 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]